Transactions
15
Insider / Latigo Biotherapeutics, Inc.
Foresite Capital Management V, LLC
Insider at Latigo Biotherapeutics, Inc.
- Company
- Latigo Biotherapeutics, Inc.
- Ticker
- LTGO
- First filing on record
- August 10, 2026
- Latest trade on record
- August 10, 2026
- SEC filings
- EDGAR ↗
Foresite Capital Management V, LLC, Insider at Latigo Biotherapeutics, Inc., has disclosed 15 transactions in LTGO since August 10, 2026: 1 purchase (1 open-market buy) and 0 sales, worth about $2.5M at the reported prices. The latest was filed August 10, 2026, 0 days after the trade.
Open-market buys
1
Sales
0
Avg. disclosure lag
0.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Foresite Capital Management V, LLC made 1 purchase worth $2.5M and no sales, plus 14 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Foresite Capital Management V, LLC has traded 1 stock on record; the largest by dollars is LTGO.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| C | Conversion of a derivative | 14 | 18,082,656 | — |
| P | Open-market purchase | 1 | 140,000 | $2.5M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 15 | 1 · $2.5M | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 195,776 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 296,880 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 3,117,664 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 742,201 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 1,125,823 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 445,320 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 3,117,664 | — | — | indirectderivative | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 296,880 | — | — | indirect | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 3,117,664 | — | — | indirect | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 195,776 | — | — | indirect | Form 4 ↗ | |
| LTGO | Buy P | August 10, 2026 | August 10, 2026 | 0d | 140,000 | $18 | $2.5M | indirectalso in another filing | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 742,201 | — | — | indirect | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 1,125,823 | — | — | indirect | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 445,320 | — | — | indirect | Form 4 ↗ | |
| LTGO | Exchange C | August 10, 2026 | August 10, 2026 | 0d | 3,117,664 | — | — | indirect | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 10, 2026 | Form 4 | 0001104659-26-093580 | 15 | published | EDGAR ↗ |
Other insiders at Latigo Biotherapeutics, Inc.
- Sanofi Insider 24 rows
- Tananbaum James B. Director 15 rows
- SEIDENBERG BETH C Director 14 rows
- Westlake BioPartners Fund I, L.P. Insider 14 rows
- 5AM Ventures VI, L.P. Insider 6 rows
- SMITH TODD N Director 1 row
Everyone on file, with contracts and lobbying under the company's name: Latigo Biotherapeutics, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 15 | August 10, 2026 | August 10, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.